Company Filing History:
1 out of 832,718 Years Active: 2020
Title: Daniela Rahmel: Innovator in Equine Metabolic Disorder Treatments
Introduction
Daniela Rahmel is a notable inventor based in Ingelheim am Rhein, Germany. She has made significant contributions to the field of veterinary medicine, particularly in the treatment of metabolic disorders in equine animals. Her innovative approach combines pharmacological treatments to address complex health issues in horses.
Latest Patents
Daniela Rahmel holds a patent for a groundbreaking invention titled "Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals." This patent focuses on the combination of one or more SGLT2 inhibitors and dopamine receptor agonists to treat or prevent various metabolic disorders in horses. The disorders addressed include Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), laminitis, and several others. This innovative treatment aims to improve the health and quality of life for equine animals suffering from these conditions.
Career Highlights
Throughout her career, Daniela has worked with prominent organizations, including Boehringer Ingelheim Vetmedica GmbH. Her work has been instrumental in advancing veterinary treatments and improving animal welfare. Daniela's dedication to research and innovation has positioned her as a key figure in her field.
Collaborations
Daniela has collaborated with various professionals, including her coworker Dania Birte Reiche. Their joint efforts have contributed to the development of effective treatments for equine health issues.
Conclusion
In summary, Daniela Rahmel is a pioneering inventor whose work in veterinary medicine has the potential to transform the treatment of metabolic disorders in equine animals. Her innovative patent and collaborations highlight her commitment to improving animal health and welfare.